Inovio Pharmaceuticals (INO) Price Target Lifted to $6 at Maxim Group

March 18, 2014 7:12 AM

Maxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE: INO) and doubled his price target from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found